Skip to main content

Table 2 Baseline characteristics of participants

From: Efficacy and safety of oxygen-sparing nasal reservoir cannula for treatment of pediatric hypoxemic pneumonia in Uganda: a pilot randomized clinical trial

  Entire Cohort (n = 16) Group Aa
(n = 8)
Group Bb
(n = 8)
Demographics
 Male sex (n, %) 8 (50) 5 (63) 3 (38)
 Age (months), median (IQR) 23 (17–29) 20 (15–28) 26 (20–32)
Past medical history
 Pneumonia 6 (38) 2 (25) 4 (50)
 Asthma 1 (6) 1 (13) 0
 HIV 0 0 0
 Malaria 3 (17) 0 3 (38)
Clinical examination
 Baseline SpO2 90 (88–93) 89 (88–92) 90 (87–93)
  85–89% 8 (50) 4 (50) 4 (50)
  90–94% 8 (50) 4 (50) 4 (50)
Weight (kg), median (IQR) 11.4 (9.0–13.0) 11.5 (9.0–13.1) 10.9 (9.5–12.6)
Temperature (°C), median (IQR) 37.4 (37–37.9) 37.4 (37.1–37.5) 37.9 (37–38.1)
Blood pressure (mmHg)3
 Systolic, median (IQR) 95 (92–101) 96 (87–104) 95 (92–100)
 Diastolic, median (IQR) 67 (62.5–78.5) 65 (60–72) 73 (65–80)
Heart Rate (bpm), median (IQR) 157 (138–168) 152 (142–160) 159 (135–179)
Respiratory rate (bpm), median (IQR) 63 (57.5–76) 66 (60–76) 63 (54–76)
Tachypnea 16 (100) 8 (100) 8 (100)
Delayed Capillary refill time 0 0 0
Absent or unequal breath sounds 0 0 0
Wheeze 1 (8) 0 1 (6)
Crackles 12 (75) 6 (75) 6 (75)
Stridor 0 0 0
Rapid or shallow breathing 16 (100) 8 (100) 8 (100)
Increased work of breathing 16 (100) 8 (100) 8 (100)
Chest wall asymmetry 0 0 0
Consciousness
 Alert 16 (100) 8 (100) 8 (100)
 Response to Voice 0 0 0
 Response to pain 0 0 0
 Unresponsive 0 0 0
SICK scores 2.1 (0.9–2.2) 1.5 (0.9–2.1) 2.1 (1.4–2.3)
Investigations, median (IQR)
 Venous blood gas
  Lactate (mmol/L) 1.8 (1.54–1.9) 1.9 (1.8–2) 1.7 (1.4–2.0)
  pH 7.4 (7.4–7.5) 7.4 (7.4–7.5) 7.5 (7.4–7.5)
  pCO2 (mmHg) 27 (24–32) 27 (25–32) 28 (24–31)
  paO2 (mmHg) 44 (43–47) 43 (42–46) 45 (43–49)
  BE (mmol/L) -5 (−8 to − 4) −6 (− 9 to − 5) −5 (− 6 to − 2)
  HCO3 (mmol/L) 19 (17–20) 18 (16–20) 20 (18–21)
 Blood glucose (mmol/L) 6 (5.2–6.9) 5.6 (5.1–6.5) 6.5 (5.5–7.0)
 Hematologic parameters
  Hemoglobin (g/dL) 11.1 (10–11.8) 11 (10–12.2) 11.1 (10–11.5)
  Hematocrit (%) 35 (31–36) 34 (31–36) 34 (31–36)
  White blood cell count (x103μL) 13 (8–18) 10 (8–21) 15 (7–18)
  Platelet count (×103 μL) 396 (271–552) 424 (320–552) 396 (260–540)
  1. Data represent n (%) unless otherwise specified
  2. IQR Interquartile Range
  3. aGroup A received OSNRC during Period 1, followed by SNC during Period 2
  4. bGroup B received SNC during Period 1, followed by OSNRC during Period 2